FDA
-
-
-
-
-
-
-
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
-
-
-
-
-
-
-
H.C. Wainwright Assumes Adicet Bio Inc. (ACET) at Buy
-
-
-
-
-
-
-
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
-
-
-
-
-
-
-
Adicet Bio (ACET) Appoints Julie Maltzman as Chief Medical Officer
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Adicet Bio Inc. (ACET)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)
-
-
-
-
-
-
-
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

